The ChAdOx1 nCoV-19 adenoviral vector vaccine to prevent contracting Covid-19 caused by infection with SARS-CoV-2 has been associated with vaccine-induced immune thrombotic thrombocytopenia (VITT) primarily leading to venous thromboses. Here, we report two cases of major arterial occlusions after ChAdOx1 nCov-19 vaccination, comprising a 42-year-old woman with thrombotic occlusion of the left carotid artery, and a 62-year-old man with occlusion of distal aorta and iliac arteries. Both were successfully treated with intravenous immunoglobulins and non-heparin anticoagulant agents leading to a beneficial short-term outcome of 6 weeks in case 1 and four months in case 2
This case series reports 40 patients (median age, 41 years [interquartile range (IQR) 32- 52, 22 men...
Vaccines for COVID-19were developed with unprecedented speedand since January 2021, the AstraZeneca/...
Thrombosis with thrombocytopenia cases reported following ChAdOx1 nCov-19 vaccination (AstraZeneca)....
The ChAdOx1 nCoV-19 adenoviral vector vaccine to prevent contracting Covid-19 caused by infection wi...
We describe the case of a 64 years-old woman admitted to the Emergency Department of the ASST-Spedal...
Abstract Background Vaccine-induced immune thrombotic thrombocytopenia is emerging as one of the mos...
The ChAdOx1 nCoV-19 adenoviral vector-based vaccine was the first to be approved against COVID-19 in...
Vaccine-induced thrombotic thrombocytopenia with cerebral venous thrombosis is a syndrome recently ...
Vaccination with ChAdOx1 nCoV-19 can result in vaccine-induced immune thrombotic thrombocytopenia (V...
6A worldwide anti-SARS-CoV-2 immunization campaign commenced at the end of 2020 using different vacc...
We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 1...
Abstract Vaccination with ChAdOx1 nCov‐19 can result in vaccine‐induced immune thrombotic thrombocyt...
Coronavirus disease 2019 (COVID-19) vaccines were developed a few months after the emergence of the ...
A case of multiple arterial thrombosis/ embolisms in a 74-year-old Caucasian man with no other cardi...
Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-1...
This case series reports 40 patients (median age, 41 years [interquartile range (IQR) 32- 52, 22 men...
Vaccines for COVID-19were developed with unprecedented speedand since January 2021, the AstraZeneca/...
Thrombosis with thrombocytopenia cases reported following ChAdOx1 nCov-19 vaccination (AstraZeneca)....
The ChAdOx1 nCoV-19 adenoviral vector vaccine to prevent contracting Covid-19 caused by infection wi...
We describe the case of a 64 years-old woman admitted to the Emergency Department of the ASST-Spedal...
Abstract Background Vaccine-induced immune thrombotic thrombocytopenia is emerging as one of the mos...
The ChAdOx1 nCoV-19 adenoviral vector-based vaccine was the first to be approved against COVID-19 in...
Vaccine-induced thrombotic thrombocytopenia with cerebral venous thrombosis is a syndrome recently ...
Vaccination with ChAdOx1 nCoV-19 can result in vaccine-induced immune thrombotic thrombocytopenia (V...
6A worldwide anti-SARS-CoV-2 immunization campaign commenced at the end of 2020 using different vacc...
We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 1...
Abstract Vaccination with ChAdOx1 nCov‐19 can result in vaccine‐induced immune thrombotic thrombocyt...
Coronavirus disease 2019 (COVID-19) vaccines were developed a few months after the emergence of the ...
A case of multiple arterial thrombosis/ embolisms in a 74-year-old Caucasian man with no other cardi...
Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-1...
This case series reports 40 patients (median age, 41 years [interquartile range (IQR) 32- 52, 22 men...
Vaccines for COVID-19were developed with unprecedented speedand since January 2021, the AstraZeneca/...
Thrombosis with thrombocytopenia cases reported following ChAdOx1 nCov-19 vaccination (AstraZeneca)....